Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$7.23 USD
+0.13 (1.83%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.20 -0.03 (-0.41%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MESO 7.23 +0.13(1.83%)
Will MESO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MESO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MESO
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
MESO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
5 Stocks to Ride the Santa Claus Rally
Other News for MESO
Mesoblast: Rolling The Dice On Cellular Medicines
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
Mesoblast Limited (MEOBF) was downgraded to a Hold Rating at Jefferies
Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
Mesoblast Eyes FDA Approval and Extends Patent Portfolio